Search results for "Proportion"

showing 10 items of 877 documents

FcγRIIa and Fc γ RIIIa Polymorphisms and Cetuximab Benefit in the Microscopic Disease

2014

Abstract Purpose: FcγR polymorphisms have been reported to enhance the immune-mediated effects of cetuximab in metastatic colorectal cancer. There are no data on the relationship between these polymorphisms and cetuximab in the early-stage setting. We performed a pharmacogenomic analysis of EXPERT-C, a randomized phase II trial of neoadjuvant CAPOX followed by chemoradiotherapy, surgery, and adjuvant CAPOX ± cetuximab in high-risk, locally advanced rectal cancer. Experimental Design: FcγRIIa-H131R and FcγRIIIa-V158F polymorphisms were analyzed on DNA from peripheral blood samples. Kaplan–Meier method and Cox regression analysis were used to calculate survival estimates and compare treatment…

OncologyCancer Researchmedicine.medical_specialtyPrognostic variableGenotypeColorectal cancermedicine.medical_treatmentCetuximabAntibodies Monoclonal HumanizedDisease-Free SurvivalInternal medicineGenotypemedicineHumansGenotypingCetuximabProportional hazards modelbusiness.industryReceptors IgGPrognosismedicine.diseaseErbB ReceptorsTreatment OutcomeOncologyImmunologyColorectal NeoplasmsbusinessAdjuvantChemoradiotherapymedicine.drugClinical Cancer Research
researchProduct

ErbB-3 predicts survival in ovarian cancer.

2006

Background HER3 (erbB-3) is a member of the epidermal growth factor receptor (EGFR) family. After dimerization with other members of the EGFR family several signal transduction cascades can be activated, including phosphoinosite 3′-kinase (PI3-K)/Akt and extracellular signal-regulated kinase (ERK1/2). Here, we studied a possible association between HER3 expression and prognosis in patients with ovarian cancer. Methods Tumor tissue of 116 consecutive patients diagnosed with primary epithelial ovarian cancer between 1986 and 1995 was analyzed immunohistochemically for HER3 expression. A possible influence of HER3 expression on survival was studied by multivariate Cox regression adjusting for …

OncologyCancer Researchmedicine.medical_specialtyReceptor ErbB-3Receptor ErbB-2ErbBPredictive Value of TestsInternal medicinemedicineBiomarkers TumorOdds RatioHumansEpidermal growth factor receptorStage (cooking)Protein kinase BNeoplasm StagingProportional Hazards ModelsGynecologyOvarian NeoplasmsbiologyProportional hazards modelbusiness.industryHazard ratioCarcinomaMiddle Agedmedicine.diseasePrognosisImmunohistochemistrySurvival AnalysisUp-RegulationGene Expression Regulation NeoplasticOncologyMultivariate Analysisbiology.proteinFemaleSignal transductionOvarian cancerbusinessJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306).

2017

Abstract Background We explored the impacts of sequential application of various treatment lines on survival kinetics. Therefore, differences in overall survival (OS) observed in FIRE-3 were investigated in the context of time and exposure to applied treatment. Patients and methods OS analyses (stratified by treatment with FOLFIRI plus either cetuximab or bevacizumab) were performed according to time intervals as well as using a Cox model to define changes of hazard ratio (HR) over time. Results The fraction of patients with systemic treatment and time on treatment markedly decreases over treatment lines and time. OS evaluation by a Cox model indicated a trend towards a non-proportional haz…

OncologyCancer Researchmedicine.medical_specialtyTime FactorsBevacizumabLeucovorinCetuximabContext (language use)Angiogenesis InhibitorsKaplan-Meier Estimatemedicine.disease_causeProto-Oncogene Proteins p21(ras)03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineBiomarkers TumorHumans030212 general & internal medicineNeoplasm MetastasisSurvival analysisProportional Hazards ModelsCetuximabProportional hazards modelbusiness.industryHazard ratioIntention to Treat AnalysisBevacizumabTreatment OutcomeOncology030220 oncology & carcinogenesisMutationFOLFIRICamptothecinKRASFluorouracilbusinessColorectal Neoplasmsmedicine.drugEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Using Cox's proportional hazards model for prognostication in carcinoma of the upper aero-digestive tract.

1992

One of the major short comings of the traditional TNM system is its limited potential for prognostication. With the development of multifactorial analysis techniques, such as Cox's proportional hazards model, it has become possible to simultaneously evaluate a large number of prognostic variables. Cox's model allows both the identification of prognostically relevant variables and the quantification of their prognostic influence. These characteristics make it a helpful tool for analysis as well as for prognostication. The goal of the present study was to develop a prognostic index for patients with carcinoma of the upper aero-digestive tract which makes use of all prognostically relevant var…

OncologyLarynxAdultMalePrognostic variablePathologymedicine.medical_specialty03 medical and health sciencesMultifactorial analysis0302 clinical medicineSurvival dataInternal medicinemedicineCarcinomaHumansBasal cell030223 otorhinolaryngologyAgedNeoplasm StagingProportional Hazards ModelsAged 80 and overHypopharyngeal NeoplasmsProportional hazards modelbusiness.industryGeneral MedicineMiddle Agedmedicine.diseasePrognosisSurvival Ratestomatognathic diseasesOropharyngeal Neoplasmsmedicine.anatomical_structureOtorhinolaryngology030220 oncology & carcinogenesisCarcinoma Squamous CellDigestive tractFemaleMouth NeoplasmsbusinessActa oto-laryngologica
researchProduct

A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen

2011

Abstract Background HIV-1 genotypic susceptibility scores (GSSs) were proven to be significant prognostic factors of fixed time-point virologic outcomes after combination antiretroviral therapy (cART) switch/initiation. However, their relative-hazard for the time to virologic failure has not been thoroughly investigated, and an expert system that is able to predict how long a new cART regimen will remain effective has never been designed. Methods We analyzed patients of the Italian ARCA cohort starting a new cART from 1999 onwards either after virologic failure or as treatment-naïve. The time to virologic failure was the endpoint, from the 90th day after treatment start, defined as the firs…

OncologyMaleAdult; Anti-HIV Agents; Cohort Studies; Drug Therapy Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Proportional Hazards Models; Treatment Failure; Viral LoadHIV InfectionsCohort Studies0302 clinical medicineANTIRETROVIRAL THERAPYMedicineHIV Infection030212 general & internal medicineTreatment Failure0303 health sciencesHealth PolicyMiddle AgedViral Load3. Good healthComputer Science ApplicationsCensoring (clinical trials)CohortCombinationlcsh:R858-859.7Drug Therapy CombinationFemaleViral loadHumanResearch ArticleCartAdultmedicine.medical_specialtyAnti-HIV AgentsHIV-1; antiretroviral therapyHealth InformaticsSettore MED/17 - MALATTIE INFETTIVElcsh:Computer applications to medicine. Medical informatics03 medical and health sciencesDrug TherapyInternal medicineHumansSurvival analysisProportional Hazards Models030306 microbiologybusiness.industryProportional hazards modelAdult; Anti-HIV Agents; Cohort Studies; Drug Therapy Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Proportional Hazards Models; Treatment Failure; Viral Load; Health Informatics; Health PolicyANTIRETROVIRAL DRUGSAnti-HIV AgentHIVGENOTYPESDiscontinuationRegimenImmunologyProportional Hazards ModelHIV-1Cohort StudiebusinessBMC Medical Informatics and Decision Making
researchProduct

Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer

2018

Background: Serum levels of neutrophils, platelets, and lymphocytes have been recognized as factors related to poor prognosis for many solid tumors, including bladder cancer (BC). Objective: To evaluate the prognostic role of the combination of the neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and lymphocyte/monocyte ratio (LMR) in patients with high-risk non–muscle-invasive urothelial BC (NIMBC). Design, setting, and participants: A total of 1151 NMIBC patients who underwent first transurethral resection of the bladder tumor (TURBT) at 13 academic institutions between January 1, 2002 and December 31, 2012 were included in this analysis. The median follow-up was 48 mo.…

OncologyMaleBladder cancer; Lymphocyte/monocyte ratio; Neutrophil/lymphocyte ratio; Platelet/lymphocyte ratio; Prognosis; Aged; Biomarkers Tumor; Blood Platelets; Carcinoma Transitional Cell; Cystectomy; Disease Progression; Female; Follow-Up Studies; Humans; Inflammation; Lymphocyte Count; Lymphocytes; Male; Monocytes; Neutrophils; Prognosis; Risk Factors; Urinary Bladder NeoplasmsNeutrophilsmedicine.medical_treatmentLymphocyte:Medicina Básica [Ciências Médicas]Prognosis.030232 urology & nephrologyMonocyteMonocytesSettore MED/24 - Urologia0302 clinical medicineRisk FactorsLymphocytesStage (cooking)Framingham Risk ScoreTumorNeutrophilBladder cancerPrognosis3. Good healthmedicine.anatomical_structureOncology030220 oncology & carcinogenesisNeutrophil/lymphocyte ratioCiências Médicas::Medicina BásicaDisease ProgressionLymphocyteFemalemedicine.symptomHumanBlood Plateletsmedicine.medical_specialtyPlatelet/lymphocyte ratioPrognosiUrologyInflammationCystectomyFollow-Up StudieCystectomy03 medical and health sciencesInternal medicinemedicineBiomarkers TumorHumansRadiology Nuclear Medicine and imagingLymphocyte CountAgedInflammationCarcinoma Transitional CellBladder cancerScience & Technologybusiness.industryProportional hazards modelRisk FactorCarcinomaLymphocyte/monocyte ratioImmunotherapymedicine.diseaseUrinary Bladder NeoplasmsBlood PlateletSurgeryTransitional CellbusinessBiomarkersFollow-Up Studies
researchProduct

Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of …

2011

Purpose The purpose of this study was to develop accurate models and nomograms to predict local recurrence, distant metastases, and survival for patients with locally advanced rectal cancer treated with long-course chemoradiotherapy (CRT) followed by surgery and to allow for a selection of patients who may benefit most from postoperative adjuvant chemotherapy and close follow-up. Patients and Methods All data (N = 2,795) from five major European clinical trials for rectal cancer were pooled and used to perform an extensive survival analysis and to develop multivariate nomograms based on Cox regression. Data from one trial was used as an external validation set. The variables used in the ana…

OncologyMaleCancer ResearchColorectal cancerMESH : AgedKaplan-Meier EstimateMESH : Randomized Controlled Trials as Topiclaw.invention[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineRandomized controlled triallawMESH : FemaleStage (cooking)Neoplasm MetastasisMESH: Models TheoreticalMESH : Rectal NeoplasmsSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIARandomized Controlled Trials as TopicMESH: Aged0303 health sciencesMESH: Middle AgedMESH : Neoplasm Recurrence LocalAge FactorsMiddle AgedMESH : Adult3. Good healthEuropeOncology030220 oncology & carcinogenesisMESH : Neoplasm MetastasisFemaleMESH: Neoplasm Recurrence LocalAdultmedicine.medical_specialtyMESH : Sex FactorsMESH : MaleMESH : Europe[SDV.CAN]Life Sciences [q-bio]/CancerMESH : Kaplan-Meier Estimate03 medical and health sciencesRECTAL CANCERSex FactorsMESH: Sex FactorsInternal medicinemedicineHumansMESH : Middle AgedSurvival analysisMESH: Kaplan-Meier Estimate030304 developmental biologyAgedMESH: Age FactorsMESH: HumansProportional hazards modelbusiness.industryRectal NeoplasmsMESH : Models TheoreticalMESH : HumansMESH: Rectal NeoplasmsMESH: AdultNomogramModels Theoreticalmedicine.diseaseMESH: Neoplasm MetastasisMESH: MaleSurgeryClinical trialMESH: Randomized Controlled Trials as TopicMESH : Age FactorsMESH: EuropeNeoplasm Recurrence LocalbusinessMESH: FemaleChemoradiotherapy
researchProduct

Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular progn…

2014

Abstract Purpose: To optimize neuroblastoma treatment stratification, we aimed at developing a novel risk estimation system by integrating gene expression–based classification and established prognostic markers. Experimental Design: Gene expression profiles were generated from 709 neuroblastoma specimens using customized 4 × 44 K microarrays. Classification models were built using 75 tumors with contrasting courses of disease. Validation was performed in an independent test set (n = 634) by Kaplan–Meier estimates and Cox regression analyses. Results: The best-performing classifier predicted patient outcome with an accuracy of 0.95 (sensitivity, 0.93; specificity, 0.97) in the validation coh…

OncologyMaleCancer ResearchMultivariate statisticsmedicine.medical_specialtyKaplan-Meier EstimateBioinformaticsRisk AssessmentNeuroblastomaText miningRisk FactorsInternal medicineNeuroblastomamedicineBiomarkers TumorCluster AnalysisHumansbusiness.industryProportional hazards modelGene Expression ProfilingReproducibility of ResultsRegression analysismedicine.diseasePrognosisClinical trialGene expression profilingGene Expression Regulation NeoplasticOncologyRegression AnalysisFemalebusinessRisk assessmentFollow-Up StudiesClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

Multi-state relative survival modelling of colorectal cancer progression and mortality.

2015

Abstract Accurate identification of factors associated with progression of colorectal cancer remains a challenge. In particular, it is unclear which statistical methods are most suitable to separate the effects of putative prognostic factors on cancer progression vs cancer-specific and other cause mortality. To address these challenges, we analyzed 10 year follow-up data for patients who underwent curative surgery for colorectal cancer in 1985–2000. Separate analyses were performed in two French cancer registries. Results of three multivariable models were compared: Cox model with recurrence as a time-dependent variable, and two multi-state models, which separated prognostic factor effects …

OncologyMaleCancer Researchmedicine.medical_specialtyEpidemiologyColorectal cancer01 natural sciencesCancer recurrence010104 statistics & probability03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansRegistries0101 mathematicsStage (cooking)AgedNeoplasm StagingModels StatisticalMulti stateRelative survivalbusiness.industryProportional hazards modelCancermedicine.diseasePrognosis3. Good healthSurgerySurvival RateOncology030220 oncology & carcinogenesisCurative surgeryDisease ProgressionFemaleNeoplasm Recurrence LocalbusinessColorectal NeoplasmsCancer epidemiology
researchProduct

c-erbB-2 expression in small-cell lung cancer is associated with poor prognosis.

2001

Small-cell lung cancer (SCLC) carries a bad prognosis despite good initial response to chemotherapy. It is therefore important to identify molecular markers that influence survival as potential new therapeutic targets. In our study, expression of the tyrosine kinase c-erbB-2 (HER2/neu) receptor in tumor tissues of 107 consecutive newly diagnosed patients with primary SCLC was quantified using a monoclonal antibody directed against the c-terminal domain of c-erbB-2. A clear-cut positive expression of c-erbB-2 was observed in 13% of patients. Surprisingly, c-erbB-2 was an independent prognostic factor (RR = 2.16; p = 0.014) when a proportional-hazard model was adjusted to stage (limited vs. e…

OncologyMaleCancer Researchmedicine.medical_specialtyPathologyLung NeoplasmsTime FactorsReceptor ErbB-2medicine.medical_treatmentSmall-cell carcinomaDisease-Free SurvivalSex FactorsInternal medicinemedicineCarcinomaHumansCarcinoma Small CellLung cancerneoplasmsAgedProportional Hazards ModelsChemotherapyPerformance statusL-Lactate DehydrogenaseProportional hazards modelbusiness.industryAge FactorsCancerAntibodies MonoclonalMiddle Agedmedicine.diseasePrognosisImmunohistochemistryProtein Structure TertiaryTreatment OutcomeOncologyPhosphopyruvate HydrataseImmunohistochemistryFemalebusinessInternational journal of cancer
researchProduct